Mini Review - (2022) Volume 10, Issue 12
Received: 02-Dec-2022, Manuscript No. jbhe-23-88198;
Editor assigned: 04-Dec-2022, Pre QC No. P-88198;
Reviewed: 18-Dec-2022, QC No. Q-88198;
Revised: 23-Dec-2022, Manuscript No. R-88198;
Published:
30-Dec-2022
, DOI: 10.37421/2380-5439.2022.12.100056
Citation: Tan, Lorenzo. “Prostate Cancer and the Microbiome: A New Target for Prevention and Treatment.” J Health Edu Res Dev 10 (2022): 100056.
Copyright: © 2022 Tan L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Sources of funding : Tan, Lorenzo. â??Prostate Cancer and the Microbiome: A New Target for Prevention and Treatment.â? J Health Edu Res Dev 10 (2022): 100056.
The Since the Human Microbiome Project was founded, more and more proof of the microbiome's influence on human health and illness has come to light. Prostate cancer, which is still the second most common male malignancy globally, may be affected significantly by changes in the microbiota makeup, according to recent studies. Research on the gut, urinary, and intra-prostate microbiome signature and the relationship with local and systemic inflammation, host immunity response, and progression has been made possible by recent advances in biological technologies, such as high-throughput sequencing, transcriptomics, and metabolomics. Numerous microbial species and their metabolites promote resurgence by increasing tumor-promoting inflammation and defective immunosurveillance or by causing genotoxin-mediated mutagenesis. However, the effect of the microbiome on growth, development, and treatment response is complicated and requires.
Gut microbiome • Hormonal • Intermittent fasting
In addition to offering fresh perspectives on the processes behind intraprostatic, gastrointestinal, and urine microbial carcinogenesis and treatment response, this review examines the state of knowledge about host-microbe interaction and the risk of. In this article, we give a thorough overview of diet modifications, gut microbiome, and cutting-edge therapeutic strategies related to the microbiome. Further research on the prostate-related microbiome and large-scale clinical trials testing the efficacy of microbiota modulation strategies may improve patient outcomes while filling the knowledge gap of microbialimmune- cancer-cell mechanistic interactions. Prostate cancer is currently the most often diagnosed non-skin cancer in the male population. Additionally, it is recognised as the main global cause of cancer-related fatalities. Future population ageing and the multifactorial, complicated illness, which is caused by a number of genetic, environmental, and physiological variables, make this condition a serious health problem. Family history, age, nutrition, ethnicity, and viral and bacterial illnesses are just a few of the variables that have been linked and tied to. In addition, various research over the past ten years have pointed to the critical function of the innate and adaptive immune system as well as the environment. There are several options for treatment that range from less invasive to more invasive . High incidence of are linked to treatments.
Despite this, many individuals have a disease return within 10 years. It is crucial to note that only 22% of patients with metastatic disease, who typically spread to the bone, experience survival. This is because metastatic disease is characterised by a tumor's significant inamorata heterogeneity, which has a significant impact on the surrounding microenvironment and a patient's response to treatment. 99% of patients with primary tumour diagnosis have a 5-year survival rate. Even while standard therapies including radiation, chemotherapy, and androgen deprivation therapy can increase patients' overall survival rates after metastatic disease, the 5-year survival rate is still still approximately 30%. These bodily regions all exhibit distinct interindividual microbial compositions, making them each represent a distinct organism. Numerous physiological processes, including inflammation, metabolism, hematopoiesis, and cognitive capacities are impacted by the microbiome. Extreme environmental change can cause the microbiome to enter a condition of dysbiosis, which can further encourage inflammatory illnesses and cancer.
A healthy symbiotic interaction between the host and its microbiota is necessary for homeostasis. The condition of chronic inflammation can be influenced by a variety of possible stressors, including microbial infections, chemical irritants, nutrition, obesity, and physical injuries. Symbiosis, a pathogenic change in the microbial species present in the genitourinary and intraprostatic tracts may cause an inflammatory condition that is predisposed to the breakdown of the epithelial barrier integrity. Epithelial damage then initiates an immune system response that recruits inflammatory cells
DNA damage due to oxidative stress, causes compensatory epithelial growth, and establishes a feed-forward process that encourages prostatic intraepithelial neoplasia. Chronic inflammation brought on by bacterial infection that also disrupts the epithelial barrier may be a major factor in the development of an inflammatory microenvironment. Bacteria and the prostate microbiome. One of the possible triggers for the inflammatory microenvironment of the prostate that promotes carcinogenesis is the microbiome and bacterial infections. Bacterial prostatitis, an infection or inflammation of the prostate gland, is known to be caused by a number of bacterial species. Leading causes of prostate inflammation include infections like bacterial prostatitis, which is commonly associated to E. coli or other Enterobacteriaceae species [1-5].
The microbiota of the genitourinary tract has been identified and consistently assessed. The human genitourinary tract is believed to be home to more than 100 species from more than 50 genera as of this writing. Formicates, Bacteroidetes, Actinobacteria, Fusobacteria, and Proteobacteria are the five major phyla that comprise the majority of the microbiome species that have been discovered thus far. These phyla also frequently contain the genera Lactobacillus, Corynebacterium, Prevotella, Staphylococcus, and Streptococcus. In contrast to the male microbiota, which has a larger number of Corynebacterium, Staphylococcus, and Streptococcus, the female microbiota is predominately made up of the genera Lactobacillus and Gardner Ella. However, there is significant interindividual variability, leading to members of the core genitourinary tract microbiome that are yet poorly characterised.
None.
There are no conflicts of interest by author.
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
